ROCK HILL, S.C., March 09, 2026 (GLOBE NEWSWIRE) — 3D Systems Corporation (NYSE:DDD) announced today its financial results for the fourth quarter and full year ended December 31, 2025.Fourth quarter revenue of $106.3 million grew 16% sequentially, above guidance of 8% to 10% growth, driven by a successful ramp-up of new printer system sales and higher materials consumption For full year 2025, the Company delivered double-digit top-line growth in personalized health services and aerospace and defense markets Cost reduction and efficiency programs delivered approximately $55 million of annualized cost savings in 2025 The Company expects to continue its momentum in top-line growth and bottom-line performance in 2026 Summary of Financial Results(Unaudited)   Three Months Ended   Year Ended(in millions, except per...

Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026  Preparing to initiate Company’s first-in-human clinical trial in HeFH patients, with early human proof-of-concept data on track for year-end 2026 Strong cash position with cash runway into the third quarter of 2027 CAMBRIDGE, Mass., March 09, 2026 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the fourth quarter and full year 2025 and provided business updates. “We achieved notable progress in the fourth quarter of 2025 as we advanced our mission and strategy to become a leader in in vivo gene editing,” said Gilmore O’Neill, M.B., M.M.Sc.,...

KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) — Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter and full year ended December 31, 2025. “With the KOMODO-1 trial of BBI-940 actively enrolling, we are excited to evaluate this potentially first-in-class oral Kinesin degrader in patients with breast cancer who are seeking new treatment options. BBI-940 is designed to disrupt ecDNA segregation...

Early GO decision reached in CAPTIVATE ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A  Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W and 300mg/2mL Q4W in generalized Myasthenia Gravis (gMG) expected to initiate in mid-2026; top-line results anticipated in 2H’28 Phase 2 MoMeNtum trial of claseprubart in Multifocal Motor Neuropathy (MMN) ongoing; top-line results on track for 2H’26 Phase 1 healthy volunteer data for DNTH212 anticipated in 2H’26; update on indication prioritization planned for 1H’26 $514.4 million of cash as of December 31, 2025 provides runway into 2028 Investor conference call and webcast to be held to discuss the CAPTIVATE trial interim responder analysis today, March 9, 2026 at 8:00 a.m. ET  NEW...

neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million in cash, cash equivalents and short-term investments supports operating plan through anticipated cash-flow break-even  Conference call to be held today, March 9, 2026, at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced financial results for the fourth quarter and full year 2025, and provided an update on the commercial launch of neffy® (epinephrine nasal spray), the first and only FDA...

Full press release available here: https://www.etexgroup.com/en/news/3216105 ZAVENTEM, Belgium, March 09, 2026 (GLOBE NEWSWIRE) — • Etex delivered a strong 2025 performance with stable revenues and slightly improved REBITDA and profitability, showing resilience in a global construction market still marked by significant challenges and in spite of adverse impacts from strengthening euro when converting non euro contributions across the group. • Revenue reached EUR 3.747 billion, a decrease of 0.8% in absolute value compared to 2024, particularly impacted by foreign currencies conversion to EUR. Like-for-like, corrected for exchange rate, it represents an increase of 1.7%. • Despite volumes remaining low, the REBITDA reached EUR 698 million, an increase of 0.4% in absolute value. Like-for-like, corrected for exchange rate, it represents...

FARGO, N.D., March 06, 2026 (GLOBE NEWSWIRE) — NI Holdings, Inc. (“NI Holdings,” or the “Company,” NASDAQ: NODK) announced today results for the year ended December 31, 2025. Summary of Year-End 2025 Results(All comparisons vs. continuing operations for the year-end 2024, unless noted otherwise)Direct written premiums were $54.1 million for the quarter, down 26% compared to the prior year quarter, and $289.8 million for the full year, down 15.3% compared to the prior year. The declines in both periods were primarily driven by the strategic decision to reduce written premiums in the Non-Standard Auto segment. This was partially offset by growth in the Home and Farm segment from new business, rate increases, and higher property values in North Dakota, South Dakota, and Nebraska, though results in South Dakota were tempered by lower...

MILWAUKEE, March 06, 2026 (GLOBE NEWSWIRE) — Enerpac Tool Group Corp. (NYSE: EPAC) announced today that it will release its second quarter fiscal 2026 earnings after the market closes on Wednesday, March 25, 2026. Management will conduct a conference call to discuss the results on Thursday, March 26, 2026, beginning at 8:30 a.m. ET / 7:30 a.m. CT. A real-time webcast of the conference call can be accessed via the Investors section of the Company’s website. For those who are unavailable to listen to the live broadcast, a replay will be available shortly after the call for 90 days. About Enerpac Tool Group Enerpac Tool Group Corp. is a premier industrial tools, services, technology, and solutions provider serving a broad and diverse set of customers and end markets for mission-critical applications in more than 100 countries. The...

ATHENS, Greece, March 06, 2026 (GLOBE NEWSWIRE) — IMPERIAL PETROLEUM INC. (NASDAQ: IMPP; the “Company”), a ship-owning company providing petroleum products, crude oil and dry bulk seaborne transportation services, announced today its unaudited financial and operating results for the fourth quarter and twelve months ended December 31, 2025. OPERATIONAL AND FINANCIAL HIGHLIGHTSFleet operational utilization of 91.8% for Q4 25’ compared to 88.7% in Q3 25’, representing the best quarterly performance in 2025. In Q4 24’ our fleet operational utilization was 86.0%. Fleet operational utilization for Q4 25’ was 90.4% for our drybulk fleet and 93.4% for our tanker fleet. Reduction of idle days in Q4 25’ by 24.3% compared to Q3 25’. About 71% of total fleet calendar days in Q4 25’ were dedicated to time charter activity while 29% to spot...

200% Q-O-Q increase in net income to $58 million in Q4 2025  $800 million of gross revenues and $161 million of net income for 2025 ($4.45 per share) $416 million in adj. EBITDA in 2025 TEN benefitting from historical high tanker rates. Timely NB orders of LNG & VLCCs $4 billion in Minimum Contracted Revenue ATHENS, Greece, March 06, 2026 (GLOBE NEWSWIRE) — TEN, Ltd (TEN) (NYSE: TEN) (the “Company”) today reported results (unaudited) for the twelve months and fourth quarter ended December 31, 2025. TWELVE MONTHS 2025 SUMMARY RESULTSTEN’s fleet for the twelve months of 2025, generated close to $800 million in gross revenues, and approx. $252 million in operating income inclusive of $12.5 million in capital gains from the sale of four older vessels. Net income for the twelve months of 2025 was $161 million or $4.45 per share. Adjusted...